Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity ...

People taking Zepbound, or interested in starting, will now have several vial options, including 2.5 mg, 5 mg, 7.5 mg and 10 ...

Eli Lilly & Co has announced a $27-billion expansion of its US manufacturing operations, adding four new sites and creating ...

At a press conference in Washington, D.C., Eli Lilly And Co (NYSE:LLY) announced its plans to bolster its domestic medicine ...

Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients: Indianapolis Wednesday, February 26, 2025, 17:00 Hrs [IST] Eli Lilly and Company announ ...

The company is doubling plans for capital spending on U.S. factories as President Donald Trump pressures the pharma industry ...

Over the last few years, as Eli Lilly has revealed a series of manufacturing investments—each one seemingly more lavish than ...

Eli Lilly is expanding the supply and cutting the costs of its weight-loss drug Zepbound, broadening access to more patients ...

Pharmaceutical giant expects the move will create 3,000 high-skilled jobs and provide work for approximately 10,000 ...

It comes as companies work to build goodwill with Trump, who has emphasized reshoring manufacturing to the U.S. and reducing ...

Zepbound may not be as widely known as its competitors, but the weight-loss drug may soon be more accessible than the rest.